Most random gene expression signatures are significantly associated with breast cancer outcome, according to a research team at Université Libre de Bruxelles.
Ipsogen Board OKs Acquisition by Qiagen
Ipsogen's board has voted in favor of the deal, and shareholders holding 61 percent of Ipsogen's stock have agreed to sell their shares to Qiagen.
Qiagen's planned acquisition of Ipsogen will provide the firm with a suite of CE-IVD marked PCR tests as well as an Affymetrix-manufactured microarray test that can be used to guide treatment for breast cancer patients.
The acquisition will also bolster Qiagen's personalized medicine play through the addition of Ipsogen's extensive portfolio of personalized diagnostics and prognostics in the area of blood cancer.
Apr 5, 2011
Ipsogen, Sysmex Reach Distribution Deal
Jan 27, 2011
Product Watch: Jan 27, 2011
Dec 15, 2010